31 results on '"Heijhuurs, Sabine"'
Search Results
2. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
3. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
4. Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
5. Supplementary Figures 1-3 from Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
6. γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs
7. Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor
8. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
9. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
10. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
11. Adding Help to an HLA-A*24:02 Tumor-Reactive gamma delta TCR Increases Tumor Control
12. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice
13. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice
14. Enhancing cancer targeting of γ9δ2TCR through modified NKG2D co-stimulation
15. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice
16. Additional file 5: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
17. Additional file 1: of Evaluating in vivo efficacy â toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
18. Additional file 6: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
19. Additional file 4: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
20. Additional file 2: of Evaluating in vivo efficacy â toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
21. Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
22. Evaluating in vivo efficacy - Toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
23. GMP-grade manufacturing of T cells engineered to express a defined γδTCR
24. Abstract LB-104: Targeting solid malignancies with TEGs: αβT cells engineered to express a defined γδTCR in xenograft mice model
25. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
26. Untouched GMP-ready purified engineered immune cells to treat cancer
27. Untouched GMP-ready purified engineered immune cells to treat cancer
28. Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
29. Towards the Next Generation CAR T Cells with TEGs: In Vivo Efficacy — Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow
30. Avidity maturation of γ9δ2T-cell receptor engineered T-cells by CDR3 modulation (162.37)
31. Towards the Next Generation CAR T Cells with TEGs: In VivoEfficacy — Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.